Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
288 studies found for:    Open Studies | "Myeloproliferative Disorders"
Show Display Options
Rank Status Study
21 Recruiting Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia
Condition: Leukemia
Intervention: Drug: Sotatercept
22 Recruiting Study of Nivolumab in Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call
23 Recruiting Evaluation of Ruxolitinib And Azacytidine Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Condition: Leukemia
Interventions: Drug: Ruxolitinib (RUX);   Drug: Azacitidine (AZA);   Behavioral: Questionnaires
24 Recruiting Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Conditions: Myeloproliferative Disease;   Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:
25 Recruiting The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Conditions: Metastatic Solid Tumor;   Lymphoma;   Myeloproliferative Neoplasms (MPN)
Intervention: Drug: PU-H71
26 Not yet recruiting PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Conditions: Chronic Phase Myelofibrosis;   Primary Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis;   Polycythemia Vera
Intervention: Drug: Pembrolizumab
27 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
28 Not yet recruiting 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
Conditions: Essential Thrombocythemia;   Primary Myelofibrosis, Fibrotic Stage;   Primary Myelofibrosis, Prefibrotic Stage;   Polycythemia Vera
Intervention: Device: Diagnostic (18F-FLT PET/CT)
29 Recruiting Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Conditions: Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
30 Recruiting SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: SGI-110;   Procedure: Donor Lymphocyte Infusion
31 Recruiting Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Conditions: Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
32 Recruiting Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Neoplasm;   Chronic Myelomonocytic Leukemia
Interventions: Drug: APR-246;   Drug: Azacitidine
33 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
34 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
35 Recruiting 8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Relapsed Adult Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia Arising From Previous Myeloproliferative Disorder
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: 8-chloro-adenosine
36 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
37 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate
38 Recruiting Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Conditions: MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention: Device: Graft Manipulation (CD34+ Selection)
39 Recruiting PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Conditions: Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
40 Recruiting TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Conditions: Myelofibrosis;   Polycythemia Vera
Interventions: Drug: TGR-1202;   Drug: ruxolitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.